Peptide Suppliers: AI Market Discovery Index

Benchmark Summary

In September 2026, Phoenix Pharmaceuticals leads the category with a valid recommendation coverage of 18.6%, down from 38.3% in July 2026. The gap to the next brand, Core Peptides at 15.1%, is 3.5 percentage points.

The largest coverage increase among tracked brands was Blue Sky Peptide, rising to 5.4% in September 2026 from 0.4% in July 2026. The largest coverage decline was Phoenix Pharmaceuticals, falling to 18.6% in September 2026 from 38.3% in July 2026.

This was a month of mixed movement. Phoenix Pharmaceuticals, Core Peptides, and Biotech Peptides each declined beyond normal month-to-month variation since July 2026, while Blue Sky Peptide rose significantly over the same period. Phoenix Pharmaceuticals declined in each of the two months since July 2026, moving from 38.3% in July 2026 to 23.4% in August 2026 and then 18.6% in September 2026. Core Peptides fell from 28.1% in July 2026 to 13.2% in August 2026, then recovered slightly to 15.1% in September 2026. The benchmark began with 530 prompt-surface observations in September 2026 and produced 350 qualified observations after qualification.

Current Benchmark at a Glance

Qualified surface breadth refers to the number of canonical AI surface families, among the six tested (ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode), that produced at least one qualified observation. Both months registered all six families. The August 2026 intermediate month also registered all six families.

For the strategic interpretation of this benchmark, read CiteWorks Studio's analysis of How AI Search Is Recommending Peptide Suppliers

Research Scope and Qualification

The public benchmark is narrower than the raw collection universe by design. The funnel below shows how observations were qualified.

Brand-level percentages use the qualified observations as the public denominator, not the raw collection. See the AI Market Discovery Methodology for details.

Current Brand Standings

This table is the primary current-month benchmark view, sorted by valid recommendation coverage.

How to Read the Standings

• Presence rate: the share of qualified observations in which the brand is mentioned at all, regardless of recommendation status.
• Valid recommendation coverage: the share of qualified observations in which the brand receives a valid recommendation, the primary benchmark metric.
• Top-three rate: the share of qualified observations in which the brand appears among the top three recommended options.
• Rank-one rate: the share of qualified observations in which the brand is the single top recommendation.
• Net sentiment: the balance of positive over negative mentions, scaled from 0 to 1.

For formulas and denominator rules, see AI Market Discovery Metric Definitions.

Recommendation Coverage Movement

Largest Increase: Blue Sky Peptide

Blue Sky Peptide's valid recommendation coverage rose 5.0 percentage points to 5.4% in September 2026, up from 0.4% in July 2026. This was a significant rise beyond normal month-to-month variation, sustained across two consecutive months. The rise was driven by coverage breadth rather than top placements, as the brand's top-three and rank-one rates remained at zero in September 2026.

Largest Decline: Phoenix Pharmaceuticals

Phoenix Pharmaceuticals' valid recommendation coverage declined 19.7 percentage points to 18.6% in September 2026, down from 38.3% in July 2026. The decline was concentrated in recommendation placement rather than presence: top-three rate fell 13.6 points to 9.4% and rank-one rate fell 4.9 points to 3.1%, while presence rate held nearly flat at 59.7% in September 2026, down from 60.2% in July 2026.

Significant Decliners: Core Peptides and Biotech Peptides

Core Peptides declined 13.0 percentage points to 15.1% in September 2026 from 28.1% in July 2026, with presence rate down 8.8 points to 26.6% and top-three rate down 10.7 points to 8.6%. Biotech Peptides declined 9.2 percentage points to 13.1% in September 2026 from 22.3% in July 2026, with its top-three rate down 9.3 points to 7.1% and rank-one rate down 8.6 points to 2.0%.

Category Leader: Phoenix Pharmaceuticals

Despite declining in each of the two months since July 2026, Phoenix Pharmaceuticals remains the category leader in valid recommendation coverage at 18.6% in September 2026. Its presence rate of 59.7% is the highest in the category, well above the next closest brand.

Stable Brands

AminoVault's coverage held within normal variation at 11.1% in September 2026, though it declined 8.7 points from 19.8% in August 2026, a move beyond normal variation for that single month. Peptides Source remained near minimal coverage at 0.9%, and Peptide Tech showed no valid recommendations in any month of the series.

Recommendation Placement Snapshot

Coverage alone does not show how prominently a brand is recommended. Among the leading brands, placement patterns differ notably.

Similar coverage levels can hide very different first-position rates. AminoVault's 11.1% coverage is paired with a 5.7% rank-one rate, while Phoenix Pharmaceuticals' higher 18.6% coverage is paired with a 3.1% rank-one rate. Core Peptides, at 15.1% coverage, ranks first in only 1.7% of observations.

Buyer-Intent Distribution

All qualified observations in each month fell into the Brand Recommendation class of buyer intent.

The current public series measures brand recommendation discovery specifically and does not yet contain qualified observations in pricing or multi-brand comparison queries.

Historical Measurement Record

This is an evergreen benchmark URL. New measurements are added to the same report.

Evidence and Source Layer

The benchmark is built from prompt-level observations that retain the query, AI/search surface, answer, brand outcome, recommendation placement, sentiment, and, where exposed, citations or attributable evidence sources. Source presence is evidence about the information environment. It is not automatically proof that the source caused the recommendation.

Scope Boundaries

This public benchmark does not measure the following:

• Market share or attributable sales
• Every possible AI response to a given query
• Organic-search ranking positions
• Social media mention volume
• Private or sponsored channels
• Causality from a metric movement alone

About This Benchmark

The LLM Authority Index AI Market Discovery Index tracks how often and how prominently brands appear in AI-generated answers across the major AI and search surfaces. This is a neutral industry benchmark; every tracked brand is treated on its own terms.

• AI Market Discovery Index
• AI Market Discovery Methodology
• AI Market Discovery Metric Definitions
• AI Market Discovery Research Standards
• Modeled AI Authority Value

Get a Company-Level Authority Index

The public industry benchmark shows category-level standings. A company-level Authority Index can go deeper.

Get my free AI Company Index